



Recombinant Protein Technical Manual  
Recombinant Human CD153/CD30L/TNFSF8 Protein  
RPES0576

### Product Data:

**Product SKU:** RPES0576

**Size:** 50µg

**Species:** Human

**Expression host:** HEK293 Cells

**Uniprot:** NP\_001235.1

### Protein Information:

**Molecular Mass:** 19.6 kDa

**AP Molecular Mass:**

**Tag:**

**Bio-activity:**

**Purity:** > 90 % as determined by reducing SDS-PAGE.

**Endotoxin:** < 1.0 EU per µg as determined by the LAL method.

**Storage:** Lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

**Shipping:** This product is provided as lyophilized powder which is shipped with ice packs.

**Formulation:** Lyophilized from sterile PBS, pH 7.4

**Reconstitution:** Please refer to the printed manual for detailed information.

**Application:**

**Synonyms:** CD153;CD30L;CD30LG

## Immunogen Information:

**Sequence:** Gln 63-Asp 234

## Background:

CD30 ligand (CD30L), also known as CD153 and TNFSF8, is a membrane-associated glycoprotein belonging to the TNF superfamily and TNFR superfamily, and is a specific ligand for CD30/TNFRSF8 originally described as a cell surface antigen and a marker for Hodgkin lymphoma and related hematologic malignancies. CD30L is a type-II membrane glycoprotein expressed on activated T cells, stimulated monocyte-macrophages, granulocytes, eosinophils, and some Burkitt-like lymphoma cell lines. CD30L is capable of transducing signals through CD30 on different CD30+ lymphoma cell lines, and mediates pleiotropic biologic effects including cell proliferation, activation, differentiation, as well as cell death by apoptosis. CD30-CD30 ligand interaction has been suggested to have a pathophysiologic role in malignant lymphomas, particularly Hodgkin disease, large cell anaplastic lymphomas and Burkitt lymphomas, and is also involved in activation and functioning of the T cell-dependent immune response. Thus, CD153 and its receptor CD30 are regarded as therapeutic targets in hematologic malignancies, autoimmune and inflammatory diseases.